Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
- Disease:Follicle centre lymphoma follicular grade I II - III refractory
- Substances:EpcoritamabLenalidomide+1
Belgium- Participants:18–64 years · 65+ years
- Substances:Epcoritamab
- Sponsor:AbbVie Deutschland GmbH & Co. KG










